Abstract Library

#1545 In Vivo Expression of Survivin and XIAP in Medullary Thyroid Carcimoma

Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5 % of all thyroid malignancies. Although surgery remains the first line therapy with curative intention, for advanced MTC current chemotherapeutic regimes do not provide promising results. Consequently, the identification of biologically relevant biomarkers that are associated with MTC progression may provide novel therapeutic targets.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Werner T

Authors: Werner T, Riemer J, Dizdar L, Wolf A, Cupisti K,

Keywords: MTC, IAP, survivin, XIAP,

#1003 Signalling Pathways in Bronchial Neuroendocrine Tumor Disease and Its Translation to Innovative Targets: The New Kid on the Block

Introduction: Bronchial neuroendocrine neoplasias comprise a wide spectrum of well-differentiated tumors (typical/atypical carcinoids) to undifferentiated carcinomas such as small (SCLC) and large cell (LC) neuroendocrine carcinomas with a fatal prognosis. Therapeutic options are unsatisfactory.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Lewens F

Authors: Lewens F, Freitag H, Briest F, Heilmann M, Schneider C,

Keywords: bronchial, NETs, PI3K, FoxM1, survivin, cell lines, SCLC,

#344 Cell Cycle Phase Expression Profile Guided Selection of Proliferative Markers for Well-differentiated Small Intestinal Neuroendocrine Neoplasms

Introduction: Grading of neuroendocrine lesions is often determined by Ki-67 (immunostain), despite limited prognostic ability for this cell cycle marker in well-differentiated tumors (WDNETs) and carcinomas.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Lawrence B, Kidd M, Alaimo D, Svejda B, Drozdov I,

Keywords: biomarker, Ki-67, NALP1, neuroendocrine tumor, PCR, proliferation, survivin, transcript,